Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis

Rheumatology

Volumn 47, Issue 10, 2008, Pages 1515-1520

  Gao, Y ^a   Chen, M ^a   Ye, H ^a   Yu, F ^a   Guo, X H ^a   Zhao, M H ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Antineutrophil cytoplasmic antibodies; Hyperthyroidism; Prognosis; Propylthiouracil; Therapy; Vasculitis

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE;

ADOLESCENT; ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; MALE; OUTCOME ASSESSMENT; PATIENT REFERRAL; PRIORITY JOURNAL; RELAPSE; REMISSION; SCHOOL CHILD; SUBTOTAL THYROIDECTOMY; THERAPY DELAY; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALGORITHMS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTITHYROID AGENTS; AUTOIMMUNE DISEASES; CHILD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; HYPERTHYROIDISM; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROGNOSIS; PROPYLTHIOURACIL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULITIS;

EID: 52949097685     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken321     Document Type: Article

References (32)

1. Choi HK, Merkel PA, Walker AM, Niles JL, Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: Prevalence among patients with high liters of antimyeloperoxidase antibodies. Arthritis Rheum 2000;43:405-13.
2. Dolman KM, Gans RO, Vervaat TJ et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993;342:651-2.
3. Gao Y, Zhao MH, Guo XH, Xin G, Gao Y, Wang HY. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism. Endocr Res 2004;30:205-13.
4. Zhao MH, Chen M, Gao Y, Wang HY. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 2006;69:1477-81.
5. Choi HK, Merkel PA, Tervaert JW, Ellack RM, McCluskey RT, Niles JL. Alternating antineutrophil cytoplasmic antibody specificity: drug-induced vasculitis in a patient with Wegener's granulomatosis. Arthritis Rheum 1999;42:384-8.
6. Slot MC, Links TP, Stegeman CA, Tervaert JW. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study. Arthritis Rheum 2006;53:108-13.
7. Gao Y, Chen M, Ye H, Guo XH, Zhao MH, Wang HY. The target antigens of antineutrophil cytoplasmic antibodies (ANCA) induced by propylthiouracil. Int Immunopharmacol 2007;7:55-60.
8. Ohtsuka M, Yamashita Y, Doi M, Hasegawa S. Propylthiouracil-induced alveolar haemorrhage associated with antineutrophil cytoplasmic antibody. Eur Respir J 1997:10:1405-7.
9. Poonathavom P, Mahachoklertwattana P, Tapaneya-Olam W, Chuansumrit A, Chunharas A. Antineutrophilic cytoplasmic antibody-positive systemic masculitis associated with propylthiouracil therapy: Report of 2 children with Graves' disease. J Med Assoc Thai 2002;85(Suppl 4):S1295-301.
10. Merkel PA. Drug-Induced vasculitis. Rheum Dis Clin North Am 2001;27:849-62.
11. Xin G, Zhao MH, Wang HY. Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in Chinese patients with clinically suspected vasculitis. Clin Diagn Lab Immunol 2004;11:559-62.
12. Zhao MH, Lockwood CM. A comprehensive method to purity three major ANCA antigens: Proteinase 3, myeloperoxidase and bactericidal/ permeability-increasing protein from human neutrophil granule acid extract. J Immunol Methods 1996;197:121-30.
13. Zhao MH, Jones SJ, Lockwood CM. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 1995;99:49-56.
14. Zhao MH, Lockwood CM. Azurocidin is a novel antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis. Clin Exp Immunol 1996;103:397-402.
15. Zhao MH, Lockwood CM. A comprehensive method to purify three major ANCA antigens: Protainase 3, myeloperoxidase and bactericidal/ permeability-increasing protein from human neutrophil granule acid extract. J Immunol Methods 1996;197:121-30,
16. Zhao MH, Liu N, Zhang YK, Wang HY. Antineutrophil cytoplasmic autoantibodies (ANCA) and their target antigens in Chinese patients with lupus nephritis. Nephrol Dial Transplant 1998;13:2821-4.
17. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiltis and glomerulonephritis. J Am Soc Neorol 1996;7:23-32.
18. Nachman PH, Hogan SL, Jannette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiltis and glomerulonephritis. J Am Soc Nephrol 1996;7:33-9.
19. Bonaci-Nikolic B, Nikolic, MM, Andrejavic S, Zoric S, Bukilica M. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: Comparison with idiopathic ANCA vasculitides. Arthritis Res Ther 2005;7:R1072-81.
20. Ma YC, Zuo L, Chen JH et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937-44.
21. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine, Pediatrics 1976;58:259-63.
22. Gunton JE, Stiel J, Caterson RJ, McElduff A. Clinical case seminar: anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endocrinol Metab 1999;84:13-6.
23. Yu F, Chen M, Gao Y et al. Clinical and pathological features of renal involvement in propylthiouracil-associated ANCA-positive vasculitis. Am J Kidney Dis 2007;49:607-14.
24. Hogan SL, Falk RJ, Chin H et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143:621-31.
25. Gao Y, Ye H, Yu F, Guo XH, Zhao MH. Anti-myeloperoxidase IgG subclass distribution and avidity in sera from patients with propylthiouracil-induced antineutrophil cytoplasmic antibodies associated vasculitis. Clin Immunol 2005;117:87-93.
26. Xu X, Zhao M, Zhang Y, Guo X, Wang H. Clinicopathological characteristics of propylthiouracil-induced antineutrophil cytoplasmic antibodies-positive vasculitis and their target antigens: A report of 4 cases and literature review. Zhonghua Nei Ke Za Zhi 2002;41:404-7.
27. Morita S, Ueda Y, Eguchi K. Anti-thyroid drug-induced ANCA-associated vasculitis: A case report and review of the literature. Endocr J 2000;47:467-70.
28. Helfgott SM, Smith RN. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21-2002. A 21-year-old man with arthritis during treatment for hyperthyroidism. N Engl J Med 2002;347:122-30.
29. Chen YX, Yu HJ, Nl LY et al. Propylthiouracil-associated antineutrophil cytoplasmic autoantibody-positive vasculitis: retrospective study of 19 cases. J Rheumatol 2007;34:2451-6.
30. Fujieda M, Hattori M, Kurayama H, Koitabashi Y. Members and Coworkers of the Japanese Society for Pediatric Nephrology. Clinical features and outcomes in children with antineutrophil cytoplasmic autoantibody-positive glomerulonephritis associated with propylthiouracil treatment. J Am Soc Nephrol 2002;13:437-45.
31. Gao Y, Chen M, Ye H, Guo XH, Zhao MH, Wang HY, Follow-up of avidity and titre of anti-myeloperoxidase antibodies in sera from patients with propylthiouracil-induced vasculitis. Clin Endocrinol 2007;66:543-7.
32. Cooper DS. Antithyroid drugs. N Engl J Med 2005;352:905-17.